OpenResearchAlpha

Current Psychiatry Reports · 17 Nov 2026

Miracle and/or Minefield? GLP-1 RA Drugs and Eating Disorders

Rachel Presskreischerh-index 2, Anna Meehan, Amanda Banks, Laura M. Thornton, Cynthia M. Bulikh-index 97

0
Citations
no database records one yet
0
Citations in 2026
so far
97
Leading author's h-index
Cynthia M. Bulik, in QAI's scholar index
84
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Purpose of Review Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of obesity and type 2 diabetes (T2D), but their rapid uptake has outpaced understanding of their effects in individuals with eating disorders (EDs). GLP-1 RAs produce sustained effects on appetite, satiety, food reward, and energy intake, raising the possibility of markedly different consequences across ED presentations. Recent Findings Preliminary studies suggest potential benefit for binge-eating symptoms, consistent with emerging evidence of overlap between binge eating and reward- and impulse-related pathways. Conversely, appetite suppression and attenuation of compensatory responses to negative energy balance could facilitate or mask restriction in individuals vulnerable to anorexia nervosa (AN) or atypical anorexia nervosa (AAN). Empirical evidence remains sparse. Summary We review neurobiological and genetic evidence relevant to these potentially divergent effects, summarize the clinical literature, and highlight implications for screening and monitoring. Determining who may benefit, who may be harmed, and how to identify risk before treatment should be priorities for future research.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Cynthia M. Bulik has the highest h-index among the authors (97).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (5)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (84)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 64 more references

A free account opens the rest of the citing papers and references on every paper’s page.

Miracle and/or Minefield? GLP-1 RA Drugs and Eating Disorders - QAI OpenResearch